Philip A. Philip

机构：Henry Ford Health System, Wayne State University · ORCID：0000-0002-6513-3491

发表论文 408 篇 · 总被引 18531 次 · h-index 71

代表论文

• SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (2024 · Journal of Clinical Oncology · 被引 53)
• Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study (2025 · Journal of Clinical Oncology · 被引 44)
• Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study (2024 · Journal of Clinical Oncology · 被引 40)
• Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges (2025 · Signal Transduction and Targeted Therapy · 被引 35)
• Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA -Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance) (2024 · Journal of Clinical Oncology · 被引 26)
• A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors (2025 · Targeted Oncology · 被引 23)